T cell infiltrate and outcome following resection of intermediate-grade primary neuroendocrine tumours and liver metastases

HPB

Volumn 12, Issue 10, 2010, Pages 674-683

  Katz, Steven C ^a,b,c   Donkor, Charan ^c   Glasgow, Kristen ^a   Pillarisetty, Venu G ^c   Gönen, Mithat ^c   Espat, N Joseph ^a,b   Klimstra, David S ^d   D'Angelica, Michael I ^c   Allen, Peter J ^c   Jarnagin, William ^c   Dematteo, Ronald P ^c   Brennan, Murray F ^c   Tang, Laura H ^d  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Department of Surgery ^*  (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

liver metastasis; neuroendocrine tumour; pancreatic tumour; T cell

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; ENDOCRINE TUMOR; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIMARY TUMOR; REGULATORY T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

EID: 78649648110     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2010.00231.x     Document Type: Article

References (26)

1. Fahy BN, D'Angelica M, DeMatteo RP, Blumgart LH, Weiser MR, Ostrovnaya I, et al. (2009) Synchronous hepatic metastases from colon cancer: changing treatment strategies and results of surgical intervention. Ann Surg Oncol 16: 361-370.
2. Kulke M,. (2005) Advances in the treatment of neuroendocrine tumours. Curr Treat Options Oncol 6: 397-409.
3. Modlin IM, Sandor A,. (1997) An analysis of 8305 cases of carcinoid tumours. Cancer 79: 813-829.
4. Oberg K, Eriksson B,. (1989) Medical treatment of neuroendocrine gut and pancreatic tumours. Acta Oncol 28: 425-431. (Pubitemid 19166905)
5. Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, Blumgart LH,. (2000) Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 190: 432-445.
6. Cho CS, Labow DM, Tang L, Klimstra DS, Loeffler AG, Leverson GE, et al. (2008) Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms. Cancer 113: 126-134.
7. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG,. (2003) Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197: 29-37.
8. Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, Pitt HA,. (2005) Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 241: 776-783; discussion 783- 785.
9. Bilimoria KY, Talamonti MS, Tomlinson JS, Stewart AK, Winchester DP, Ko CY, Bentrem DJ,. (2008) Prognostic score predicting survival after resection of pancreatic neuroendocrine tumours: analysis of 3851 patients. Ann Surg 247: 490-500.
10. Ferrone CR, Tang LH, Tomlinson J, Gonen M, Hochwald SN, Brennan MF, et al. (2007) Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol 25: 5609-5615.
11. Gullo L, Migliori M, Falconi M, Pederzoli P, Bettini R, Casadei R, et al. (2003) Non-functioning pancreatic endocrine tumours: a multicentre clinical study. Am J Gastroenterol 98: 2435-2439.
12. Hochwald SN, Zee S, Conlon KC, Colleoni R, Louie O, Brennan MF, Klimstra DS,. (2002) Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 20: 2633-2642.
13. Phan GQ, Yeo CJ, Hruban RH, Littemoe KD, Pitt HA, Cameron JL,. (1998) Surgical experience with pancreatic and peripancreatic neuroendocrine tumours: review of 125 patients. J Gastrointest Surg 2: 473-482.
14. Vagefi PA, Razo O, Deshpande V, McGrath DJ, Lauwers GY, Thayer SP, et al. (2007) Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005. Arch Surg 142: 347-354.
15. Reidy DL, Tang LH, Saltz LB,. (2009) Treatment of advanced disease in patients with well-differentiated neuroendocrine tumours. Nat Clin Pract Oncol 6: 143-152.
16. Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T, et al. (2007) FoxP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 13: 902-911.
17. Sasaki A, Tanaka F, Mimori K, Inoue H, Kai S, Shibata K, et al. (2008) Prognostic value of tumour-infiltrating FoxP3+ regulatory T cells in patients with hepatocellular carcinoma. Eur J Surg Oncol 34: 173-179.
18. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. (2006) Type, density, and location of immune cells within human colorectal tumours predict clinical outcome. Science 313: 1960-1964.
19. Galon J, Fridman WH, Pages F,. (2007) The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 67: 1883-1886.
20. Katz SC, Pillarisetty V, Bamboat ZM, Shia J, Hedvat C, Gonen M, et al. (2009) T cell infiltrate predicts longterm survival following resection of colorectal cancer liver metastases. Ann Surg Oncol 16: 2524-2530.
21. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353: 2654-2666.
22. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203-213.
23. Cohen T, Prus D, Shia J, Abu-Wasel B, Pinto MG, Freund HR, et al. (2008) Expression of P53, P27 and KI-67 in colorectal cancer patients of various ethnic origins: clinical and tissue microarray based analysis. J Surg Oncol 97: 416-422.
24. Hori S, Nomura T, Sakaguchi S,. (2003) Control of regulatory T cell development by the transcription factor FoxP3. Science 299: 1057-1061.
25. Ryschich E, Autschbach F, Eisold S, Klar E, Buchler MW, Schmidt J,. (2003) Expression of HLA class I/II antigens and T cell immune response in human neuroendocrine tumours of the pancreas. Tissue Antigens 62: 48-54.
26. Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B, et al. (2007) Increased regulatory T cells correlate with CD8 T cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 132: 2328-2339.